Levodopa-induced oromandibular dystonia in progressive supranuclear palsy

Clinical Neurology and Neurosurgery

Volumn 105, Issue 2, 2003, Pages 132-134

  Tan, E K ^a,b,c   Chan, L L ^a   Wong, M C ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^c Singapore Health Services   (Singapore)

Author keywords

Dystonia; Levodopa induced; Progressive supranuclear palsy

Indexed keywords

LEVODOPA; LONG ACTING DRUG;

AGED; ARTICLE; BRUXISM; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DOSE RESPONSE; DYSPHAGIA; DYSTONIA; HUMAN; JAW MOVEMENT; MALE; MEDICAL EXAMINATION; MUSCLE HYPERTROPHY; MUSCLE SPASM; OROMANDIBULAR DYSTONIA; PROGRESSIVE SUPRANUCLEAR PALSY; SPEECH; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; DYSTONIA; HUMANS; LEVODOPA; MALE; MANDIBLE; MOUTH; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 0347156843     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-8467(02)00128-2     Document Type: Article

References (18)

1. Tan E.K., Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J. Neurol. Neurosurg. Psychiatry. 68:2000;186-190.
2. Tan E.K., Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 53:1999;2102-2107.
3. Tolosa E., Marti M.J. Blepharospasm-oromandibular dystonia (Meige's syndrome): clinical aspects. Adv. Neurol. 49:1988;73-84.
4. Jankovic J. Etiology and differential diagnosis of blepharospasm and orromandibular dystonia. Adv. Neurol. 49:1988;103-116.
5. Litvan I. Progressive supranuclear palsy revisited. Acta. Neurol. Scand. 98:1998;73-84.
6. Rivest J., Quinn N., Marsden C.D. Dystonia in Parkinson's disease, multiple system atrophy and progressive supranuclear gaze palsy. Neurology. 40:1990;1571-1578.
7. De Bruin V.M.S., Lees A.J. Subcortical neurofibrillary degeneration presenting as Steele-Richardson-Olszewski and other related syndromes: a review of 90 pathologically verified cases. Mov. Disord. 9:1994;381-391.
8. Jankovic J., Friedman D.I., Pirozzolo F.J., McGrary J.A. Progressive supranuclear gaze palsy: motor, neurobehavioural and neuro-ophthalmological findings. Streifler M.B., Korczyn A.D., Melamed E., Youdim M.B.H. Advances in Neurology. 53:1990;293-304 Raven Press, New York.
9. David N.J., Mackey E.A., Smith J.L. Further observations in progressive supranuclear palsy. Neurology. 18:1968;349-356.
10. Anzil A.P. Progressive supranulcear palsy: case report with pathological findings. Acta. Neuropathol. 14:1969;72-76.
11. Collins S.J., Ahlskog J.E., Parisi J.E., Maraganore D.M. Progressive supranuclear palsy: neuropathologically based diagnostic criteria. J. Neurol. Neurosurg. Psychiatry. 58:1995;167-173.
12. Muller J., Wenning G.K., Wissel J., Seppi K., Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J. Neurol. 249:2002;300-304.
13. Oide T., Ohara S., Yazawa M., Inoue K., Itoh N., Tokuda T., Ikeda S. Progressive supranuclear palsy with asymmetric tau pathology presenting with unilateral limb dystonia. Acta. Neuropathol. (Berl). 104:2002;209-214.
14. Barclay C.L., Lang A.E. Dystonia in progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiatry. 62:1997;352-356.
15. Weiner W.J., Nausieda P. Meige's syndrome during long-term dopaminergic therapy in Parkinson's disease. Arch. Neurol. 39:1982;451-452.
16. Boesch S.M., Wenning G.K., Ransmayr G., Poewe W. Dystonia in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry. 72:2002;300-303.
17. 3H)spiperone binding. Brain Res. 379:1986;294-299.
18. Olanow C.W., Obeso J.A. Preventing levodopa-induced dyskinesias. Ann. Neurol. 47:2000;167-178.